SYS-CON MEDIA Authors: Michael Bushong, PR.com Newswire, David Smith, Tim Crawford, Kevin Benedict

News Feed Item

Dilon Acquires RMD Navigator Gamma Probes

NEWPORT NEWS, Va., Jan. 6, 2014 /PRNewswire/ -- Dilon Technologies Inc. announced today that they acquired the assets of the Navigator gamma probe business from RMD Instruments Corp., a subsidiary of Dynasil Corporation of America.

(Logo: http://photos.prnewswire.com/prnh/20140106/PH40697LOGO )

RMD Instruments has over thirty years experience in the manufacturing and marketing of a quality range of intra operative surgical probes which are distributed both in the US and internationally and which bring clinically effective solutions to medical professionals.  The acquired products are used in surgery for procedures such as Sentinel Lymph Node Biopsy and Pulmonary Wedge Resection. The company recently introduced its "Navigator 2.0™" wireless probe which has been very well received by the market place.

"In addition to our market leadership in the small field of view molecular breast imaging market, this acquisition is consistent with our objective of expanding our product offering in both the diagnostic and surgical segments of the market and comes on the heels of our recent agreement with Digirad," commented Robert G. Moussa, Dilon's CEO.

"We are pleased to have found a wonderful home for our Navigator Probe technology, one of the most widely used Gamma probes for cancer surgery in the marketplace.  Dilon Technologies is well situated to expand the gamma probe market and we look forward to working with them over the coming months to transition the product from our manufacturing facility to Dilon," commented Peter Sulick, Dynasil's Chairman and Interim CEO.

For the time being, Dynasil will continue to manufacture and distribute the products, ensuring continuity in supply and regulatory compliance.

About Dilon
Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon Molecular Imaging System, is a high-resolution, small field-of-view digital gamma camera, optimized for MBI/BSGI. MBI utilizes radiotracer uptake to detect the increased metabolic activity of breast lesions and therefore, is not affected by breast density. Both the Dilon 6800® and Acella® systems provide high photon sensitivity; and Dilon's GammaLoc® System is the only localization device on the market to enable molecular-guided breast biopsy. Many leading medical centers around the country are now offering MBI to their patients, including: Beth Israel and Cornell University Medical Centers in New York; Kaiser Permanente of Sacramento, CA, and The George Washington University, Washington D.C. For more information, please visit www.dilon.com.

About Dynasil
Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures detection and analysis technology, precision instruments and optical components for the homeland security, medical and industrial markets including medical imaging and sensors for non-destructive testing. Dynasil has an impressive and growing portfolio of issued and pending U.S. patents. The Company is based in Watertown, Massachusetts, with additional operations in MA, MN, NY, NJ and the United Kingdom. More information about the Company is available at www.dynasil.com.

About Digirad
Digirad Corporation is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers, and also sells medical diagnostic imaging systems for nuclear cardiology and general nuclear medicine applications. For more information, please visit www.digirad.com. Dilon is the exclusive international distributor (most countries outside the U.S.) of Digirad's lines of molecular imaging cameras.Digirad® and Cardius® are registered trademarks of Digirad Corporation.

Media Contact: Pjerin Luli
Dilon Technologies, Inc.
1 (757) 269-4910 x321
[email protected] 

SOURCE Dilon Technologies Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.